[177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study

被引：28

作者：

Singh, Simron

Halperin, Daniel M.

Myrehaug, Sten

Herrmann, Ken

Pavel, Marianne

Kunz, Pamela L.

Chasen, Beth

Capdevila, Jaume

Tafuto, Salvatore

Oh, Do-Youn

Yoo, Changhoon

Falk, Stephen

Halfdanarson, Thorvardur Ragnar

Folitar, Ilya

Zhang, Yufen

Santoro, Paola

Aimone, Paola

de Herder, Wouter W.

Ferone, Diego

机构：

[1] Univ Toronto, Sunnybrook Odette Canc Ctr, Div Med Oncol, Toronto, ON, Canada

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[3] Univ Toronto, Toronto, ON, Canada

[4] Univ Duisburg Essen, Dept Nucl Med, Essen, Germany

[5] Univ Hosp Essen, German Canc Consortium DKTK, Essen, Germany

[6] Friedrich Alexander Univ Erlangen Nurnberg, Uniklinikum Erlangen, Erlangen, Germany

[7] Yale Sch Med, New Haven, CT USA

[8] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[9] Ist Nazl Tumori IRCCS, Oncol Clin & Sperimentale Sarcomi & Tumori Rari, Naples, Italy

[10] Seoul Natl Univ Hosp, Canc Res Inst, Seoul, South Korea

[11] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[12] Univ Hosp Bristol NHS Fdn Trust, Bristol Haematol & Oncol Ctr, Bristol, England

[13] Mayo Clin, Rochester, MN USA

[14] Novartis Pharm AG, Basel, Switzerland

[15] Novartis Pharmaceut, E Hanover, NJ USA

[16] Erasmus MC, Rotterdam, Netherlands

[17] Univ Genoa, IRCCS Policlin San Martino, Genoa, Italy

[18] Univ Genoa, DiMI, Genoa, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期

关键词：

D O I：

10.1200/JCO.2024.42.3_suppl.LBA588

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：LBA588 / LBA588

页数：1